Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer
Jacqulyne Robichaux(The University of Texas MD Anderson Cancer Center), Yasir Y. Elamin(The University of Texas MD Anderson Cancer Center), Zhi Tan(The University of Texas MD Anderson Cancer Center), Brett W. Carter(The University of Texas MD Anderson Cancer Center), Shuxing Zhang(The University of Texas MD Anderson Cancer Center), Shengwu Liu(Dana-Farber Cancer Institute), Shuai Li(Dana-Farber Cancer Institute), Ting Chen(Dana-Farber Cancer Institute), Alissa Poteete(The University of Texas MD Anderson Cancer Center), Adriana Estrada‐Bernal(University of Colorado Cancer Center), Anh T. Le(University of Colorado Cancer Center), Anna Truini(Yale University), Monique B. Nilsson(The University of Texas MD Anderson Cancer Center), Huiying Sun(The University of Texas MD Anderson Cancer Center), Emily Roarty(The University of Texas MD Anderson Cancer Center), Sarah B. Goldberg(Yale University), Julie R. Brahmer(Johns Hopkins University), Mehmet Altan(The University of Texas MD Anderson Cancer Center), Charles Lu(The University of Texas MD Anderson Cancer Center), Vassiliki A. Papadimitrakopoulou(The University of Texas MD Anderson Cancer Center), Katerina Politi(Yale University), Robert C. Doebele(University of Colorado Denver), Kwok‐Kin Wong(NYU Langone Health), John V. Heymach(The University of Texas MD Anderson Cancer Center)
Cited by 453
Abstract
Related Papers
No related papers found
Powered by citation graph analysis